Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Infection susceptibility increased? 118 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 118 reports of Infection susceptibility increased have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.2% of all adverse event reports for OCRELIZUMAB.

118
Reports of Infection susceptibility increased with OCRELIZUMAB
0.2%
of all OCRELIZUMAB reports
3
Deaths
32
Hospitalizations

How Dangerous Is Infection susceptibility increased From OCRELIZUMAB?

Of the 118 reports, 3 (2.5%) resulted in death, 32 (27.1%) required hospitalization, and 3 (2.5%) were considered life-threatening.

Is Infection susceptibility increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 118 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Infection susceptibility increased?

ADALIMUMAB (179) ETANERCEPT (160) METHOTREXATE (95) PREDNISONE (67) DIMETHYL (64) MYCOPHENOLATE MOFETIL (64) PREDNISOLONE (62) SECUKINUMAB (59) TOFACITINIB (57) APREMILAST (53)

Which OCRELIZUMAB Alternatives Have Lower Infection susceptibility increased Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Infection susceptibility increased Reports All Drugs Causing Infection susceptibility increased OCRELIZUMAB Demographics